Estradiol News and Research

RSS

Estradiol is a sex hormone. Mislabelled the "female" hormone, it is also present in males; it represents the major estrogen in humans. Estradiol has not only a critical impact on reproductive and sexual functioning, but also affects other organs including the bones.

Women with menopausal transition experience cognitive difficulties

The memory problems that many women experience in their 40s and 50s as they approach and go through menopause are both real and appear to be most acute during the early period of post menopause. That is the conclusion of a study which appears today in the journal Menopause.

4 Jan 2013

BMI influences hormone levels in overweight, obesity

A high body mass index has no significant impact on parameters of sperm quality, although it does lower serum levels of testosterone, luteinizing hormone, and prolactin, say researchers.

5 Dec 2012

Drospirenone-containing birth control pills associated with increased risk of blood clots

A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) - commonly referred to as blockage of arteries and blood clots, respectively - associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives.

20 Oct 2012

Study finds low testosterone levels among obese teen boys

A study by the University at Buffalo shows for the first time that obese males ages 14 to 20 have up to 50 percent less total testosterone than do normal males of the same age, significantly increasing their potential to be impotent and infertile as adults.

17 Oct 2012

Sleep deprivation reduces aggression, testosterone in men

Sleep deprivation is associated with a reduction in reactive aggression and testosterone levels in men, Canadian study findings show.

16 Oct 2012

Contraceptive patch suppresses ovulation in obese, nonobese women

Use of a novel transdermal contraceptive patch suppresses ovulation in obese and nonobese women, research shows.

12 Oct 2012

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

The American Association for Cancer Research will host the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research at the Hilton Anaheim from Oct. 16-19, 2012.

12 Oct 2012

Estrogen/progesterone treatment started soon after menopause appears safe and effective

Estrogen/progesterone treatment started soon after menopause appears safe and relieves many of the symptoms menopausal women face as well as improving mood and markers of cardiovascular risk, according to a multicenter randomized study presented at the North American Menopause Society (NAMS) Annual Meeting in Orlando, Florida.

4 Oct 2012

Assisted reproduction technology may increase risk of MS activity among women

Researchers in Argentina report that women with multiple sclerosis (MS) who undergo assisted reproduction technology (ART) infertility treatment are at risk for increased disease activity.

4 Oct 2012

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis

Antares Pharma, Inc. today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX).

25 Sep 2012

Oral contraceptive use can lead to increased pain during intercourse among young women

According to the Guttmacher Institute, over ten million women in the US use oral contraceptives. Although birth control pills are an effective way to prevent pregnancy, keep acne at bay, and treat menstrual pain or irregularity, there may be some health concerns that are undisclosed to patients. A recent study suggests that oral contraceptive use can lead to increased pain during intercourse, with decreased libido and spontaneous arousability as well as diminished frequency of sexual intercourse and orgasm in young women.

19 Sep 2012

FDA accepts Teva's NDA for Quartette oral contraceptive

Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets).

13 Aug 2012

Combination therapy delays progression for metastatic breast cancer patients

Phase III trial results show that a combination of the aromatase inhibitor anastrozole and fulvestrant, an analog of estradiol that downgrades the estrogen receptor, is superior to anastrozole alone in prolonging progression-free survival in patients with metastatic breast cancer.

10 Aug 2012

FDA approves Lupin’s Norgestimate and Ethinyl Estradiol Tablets

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. has received approval for its Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg from the United States Food and Drugs Administration (FDA).

4 Jul 2012

Imaging PR status may help identify tumor response to endocrine therapy

Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage.

3 Jul 2012

Noven Pharmaceuticals provides update on status of generic Lidoderm ANDA

Noven Pharmaceuticals, Inc. today provided an update on the status of its pending Abbreviated New Drug Application (ANDA) seeking approval to market a lidocaine topical patch 5%. Noven's lidocaine topical patch 5% is a generic version of Endo Pharmaceuticals' Lidoderm.

30 Jun 2012

Prenatal exposure to BPA appears to program uterine estrogen responsiveness in adulthood

Prenatal exposure to bisphenol A, or BPA, a chemical found in many common plastic household items, can cause numerous genes in the uterus to respond differently to estrogen in adulthood, according to a study using a mouse model. The results will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

Positive results from Antares Pharma's VIBEX MTX human factors usability study for RA

Antares Pharma, Inc. today announced positive results from a human factors usability study for VIBEX Methotrexate (MTX), a proprietary auto injector product designed to self-administer a rapid subcutaneous weekly injection of methotrexate for the treatment of rheumatoid arthritis (RA).

26 Jun 2012

Menopausal women with high oestradiol levels at greater risk of strokes

Women are less prone to cardiovascular disease then men; but this difference between the sexes becomes less marked after the menopause. This observation is behind a great deal of received wisdom, where oestrogen is assumed to have a beneficial effect on the heart and blood vessels.

11 Jun 2012

BioSante to initiate two new LibiGel Phase III efficacy trials in FSD, HSDD

BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).

11 Jun 2012